Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., Gitt M.A., Hirabayashi J., Hughes C., Kasai K., Leffler H., Liu F., Lotan R., Mercurio A.M., Monsigny M., Pillai S., Poirier F., Raz A., Rigby P.W.J., Rini J., Wang J.L. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
Thijssen V.L., Rabinovich G.A., Griffioen A.W. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 2013, 24:547-558.
Barondes S.H., Cooper D.N., Gitt M.A., Leffler H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 1994, 269:20807-20810.
Ideo H., Seko A., Yamashita K. Recognition mechanism of galectin-4 for cholesterol 3-sulfate. J. Biol. Chem. 2007, 282:21081-21089.
Ahmad N., Gabius H.J., Andre S., Kaltner H., Sabesan S., Roy R., Liu B., Macaluso F., Brewer C.F. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 2004, 279:10841-10847.
Elola M.T., Wolfenstein-Todel C., Troncoso P., Vasta G.R., Rabinovich G.A. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell. Mol. Life Sci. 2007, 64:1679-1700.
Compagno D., Jaworski F., Gentilini L., Contrufo G., Pérez I.G., Elola M.T., Rabinovich G.A., Pregi N., Laderach D. Galectins: major signaling modulators inside and outside the cell. Curr. Mol. Med. 2014, 14:630-651.
Liu F.T., Patterson R.J., Wang J.L. Intracellular functions of galectins. Biochim. Biophys. Acta 2002, 1572:263-273.
Liu F.T., Yang R.Y., Saegusa J., Chen H.Y., Hsu D.K. Galectins in regulation of apoptosis. Adv. Exp. Med. Biol. 2011, 705:431-442.
Danguy A., Camby I., Kiss R. Galectins and cancer. Biochim. Biophys. Acta 2002, 1572:285-293.
Balan V., Nangia-Makker P., Raz A. Galectins as cancer biomarkers. Cancers (Basel) 2010, 2:592-610.
Giordano M., Croci D.O., Rabinovich G.A. Galectins in hematological malignancies. Curr. Opin. Hematol. 2013, 20:327-335.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: structure, function and therapeutic potential. Expert. Rev. Mol. Med. 2008, 10:e17.
Rabinovich G.A., Croci D.O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012, 36:322-335.
Oberg C.T., Leffler H., Nilsson U.J. Inhibition of galectins with small molecules. Chimia (Aarau) 2011, 65:18-23.
Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15975-15980.
Dalotto-Moreno T., Croci D.O., Cerliani J.P., Martinez-Allo V.C., Dergan-Dylon S., Méndez-Huergo S.P., Stupirski J.C., Mazal D., Osinaga E., Toscano M.A., Sundblad V., Rabinovich G.A., Salatino M. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 2013, 73:1107-1117.
Croci D.O., Salatino M., Rubinstein N., Cerliani J.P., Cavallin L.E., Leung H.J., Ouyang J., Ilarregui J.M., Toscano M.A., Domaica C.I., Croci M.C., Shipp M.A., Mesri E.A., Albini A., Rabinovich G.A. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J. Exp. Med. 2012, 209:1985-2000.
John C.M., Leffler H., Kahl-Knutsson B., Svensson I., Jarvis G.A. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin. Cancer Res. 2003, 9:2374-2383.
Mirandola L., Yu Y., Chui K., Jenkins M.R., Cobos E., John C.M., Chiriva-Internati M. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One 2011, 6:e21811.
Blanchard H., Yu X., Collins P.M., Bum-Erdene K. Galectin-3 inhibitors: a patent review (2008-present). Expert Opin. Ther. Pat. 2014, 1-13.
van den BrÛle F.A., Waltregny D., Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J. Pathol. 2001, 193:80-87.
Kohrenhagen N., Volker H.U., Kapp M., Dietl J., Kammerer U. Increased expression of galectin-1 during the progression of cervical neoplasia. Int. J. Gynecol. Cancer 2006, 16:2018-2022.
Kim H.J., Jeon H.K., Cho Y.J., Park Y.A., Choi J.J., Do I.G., Song S.Y., Lee Y.Y., Choi C.H., Kim T.J., Bae D.S., Lee J.W., Kim B.G. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur. J. Cancer 2012, 48:1914-1921.
Jung E.J., Moon H.G., Cho B.I., Jeong C.Y., Joo Y.T., Lee Y.J., Hong S.C., Choi S.K., Ha W.S., Kim J.W., Lee C.W., Lee J.S., Park S.T. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int. J. Cancer 2007, 120:2331-2338.
Sanjuán X., Fernández P.L., Castells A., Castronovo V., van den Brule F., Liu F.T., Cardesa A., Campo E. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997, 113:1906-1915.
Spano D., Russo R., Di Maso V., Rosso N., Terracciano L.M., Roncalli M., Tornillo L., Capasso M., Tiribelli C., Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol. Med. 2010, 16:102-115.
Chen R., Pan S., Ottenhof N.A., de Wilde R.F., Wolfgang C.L., Lane Z., Post J., Bronner M.P., Willmann J.K., Maitra A., Brentnall T.A. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 2012, 13:899-907.
Berberat P.O., Friess H., Wang L., Zhu Z., Bley T., Frigeri L., Zimmermann A., Büchler M.W. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J. Histochem. Cytochem. 2001, 49:539-549.
Tang D., Yuan Z., Xue X., Lu Z., Zhang Y., Wang H., Chen M., An Y., Wei J., Zhu Y., Miao Y., Jiang K. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int. J. Cancer 2012, 130:2337-2348.
Shen J., Person M.D., Zhu J., Abbruzzese J.L., Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64:9018-9026.
Abroun S., Otsuyama K., Shamsasenjan K., Islam A., Amin J., Iqbal M.S., Gondo T., Asaoku H., Kawano M.M. Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro. Br. J. Haematol. 2008, 142:754-765.
D'Haene N., Maris C., Sandras F., Dehou M.F., Remmelink M., Decaestecker C., Salmon I. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int. J. Immunopathol. Pharmacol. 2005, 18:431-443.
Koopmans S.M., Bot F.J., Schouten H.C., Janssen J., van Marion A.M. The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. Am. J. Blood Res. 2012, 2:119-127.
Cindolo L., Benvenuto G., Salvatore P., Pero R., Salvatore G., Mirone V., Prezioso D., Altieri V., Bruni C.B., Chiariotti L. galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int. J. Cancer 1999, 84:39-43.
Gillenwater A., Xu X.C. A.K. el-Naggar, G.L. Clayman, R. Lotan, Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996, 18:422-432.
Kuo P.L., Hung J.Y., Huang S.K., Chou S.H., Cheng D.E., Jong Y.J., Hung C.H., Yang C.J., Tsai Y.M., Hsu Y.L., Huang M.S. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J. Immunol. 2011, 186:1521-1530.
Langbein S., Brade J., Badawi J.K., Hatzinger M., Kaltner H., Lensch M., Specht K., André S., Brinck U., Alken P., Gabius H.J. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Histopathology 2007, 51:681-690.
Szoke T., Kayser K., Baumhakel J.D., Trojan I., Furak J., Tiszlavicz L., Horvath A., Szluha K., Gabius H.J., Andre S. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005, 69:167-174.
Tang C.E., Tan T., Li C., Chen Z.C., Ruan L., Wang H.H., Su T., Zhang P.F., Xiao Z.Q. Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol. Rep. 2010, 24:495-500.
von Klot C.A., Kramer M.W., Peters I., Hennenlotter J., Abbas M., Scherer R., Herrmann T.R., Stenzl A., Kuczyk M.A., Serth J., Merseburger A.S. Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. BMC Clin. Pathol. 2014, 14:15.
Chiariotti L., Berlingieri M.T., Battaglia C., Benvenuto G., Martelli M.L., Salvatore P., Chiappetta G., Bruni C.B., Fusco A. Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int. J. Cancer 1995, 64:171-175.
Torres-Cabala C., Bibbo M., Panizo-Santos A., Barazi H., Krutzsch H., Roberts D.D., Merino M.J. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol. 2006, 50:518-528.
Xu X.C. A.K. el-Naggar, R. Lotan, Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 1995, 147:815-822.
Cada Z., Smetana K., Lacina L., Plzáková Z., Stork J., Kaltner H., Russwurm R., Lensch M., André S., Gabius H.J. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol. (Praha) 2009, 55:145-152.
Mathieu V., de Lassalle E.M., Toelen J., Mohr T., Bellahcène A., Van Goietsenoven G., Verschuere T., Bouzin C., Debyser Z., De Vleeschouwer S., Van Gool S., Poirier F., Castronovo V., Kiss R., Feron O. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J. Invest. Dermatol. 2012, 132:2245-2254.
Choufani G., Nagy N., Saussez S., Marchant H., Bisschop P., Burchert M., Danguy A., Louryan S., Salmon I., Gabius H.J., Kiss R., Hassid S. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 1999, 86:2353-2363.
Makino K., Kawamura K., Sato W., Kawamura N., Fujimoto T., Terada Y. Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling. PLoS One 2012, 7:e41049.
Chung H., Kim B., Jung S.H., Won K.J., Jiang X., Lee C.K., Lim S.D., Yang S.K., Song K.H., Kim H.S. Does phosphorylation of cofilin affect the progression of human bladder cancer?. BMC Cancer 2013, 13:45.
Ding Y.M., Dong J.H., Chen L.L., Zhang H.D. Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development. Oncol. Rep. 2009, 21:983-987.
Zhong L.P., Wei K.J., Yang X., Pan H.Y., Ye D.X., Wang L.Z., Zhang Z.Y. Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2010, 136:1527-1535.
He Q.Y., Chen J., Kung H.F., Yuen A.P., Chiu J.F. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4:271-278.
van den Brule F.A., Buicu C., Berchuck A., Bast R.C., Deprez M., Liu F.T., Cooper D.N., Pieters C., Sobel M.E., Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum. Pathol. 1996, 27:1185-1191.
Saal I., Nagy N., Lensch M., Lohr M., Manning J.C., Decaestecker C., André S., Kiss R., Salmon I., Gabius H.J. Human galectin-2: expression profiling by RT-PCR/immunohistochemistry and its introduction as a histochemical tool for ligand localization. Histol. Histopathol. 2005, 20:1191-1208.
de Matos L.L., Del Giglio A.B., Matsubayashi C.O., de Lima Farah M., Del Giglio A., da Silva Pinhal M.A. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn. Pathol. 2012, 7:97.
Collet J.F., Hurbain I., Prengel C., Utzmann O., Scetbon F., Bernaudin J.F., Fajac A. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br. J. Cancer 2005, 93:1175-1181.
Bryson P.C., Shores C.G., Hart C., Thorne L., Patel M.R., Richey L., Farag A., Zanation A.M. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch. Otolaryngol. Head Neck Surg. 2008, 134:581-586.
Bartolazzi A., Gasbarri A., Papotti M., Bussolati G., Lucante T., Khan A., Inohara H., Marandino F., Orlandi F., Nardi F., Vecchione A., Tecce R., Larsson O. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357:1644-1650.
Wang Y., Nangia-Makker P., Tait L., Balan V., Hogan V., Pienta K.J., Raz A. Regulation of prostate cancer progression by galectin-3. Am. J. Pathol. 2009, 174:1515-1523.
Castronovo V., Liu F.T., van den Brule F.A. Decreased expression of galectin-3 in basal cell carcinoma of the skin. Int. J. Oncol. 1999, 15:67-70.
Kapucuoglu N., Basak P.Y., Bircan S., Sert S., Akkaya V.B. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol. Res. Pract. 2009, 205:97-103.
Mollenhauer J., Deichmann M., Helmke B., Müller H., Kollender G., Holmskov U., Ligtenberg T., Krebs I., Wiemann S., Bantel-Schaal U., Madsen J., Bikker F., Klauck S.M., Otto H.F., Moldenhauer G., Poustka A. Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int. J. Cancer 2003, 105:149-157.
Abdou A.G., Hammam M.A., Farargy S.E., Farag A.G., El Shafey E.N., Farouk S., Elnaidany N.F. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am. J. Dermatopathol. 2010, 32:809-814.
Brown E.R., Doig T., Anderson N., Brenn T., Doherty V., Xu Y., Bartlett J.M., Smyth J.F., Melton D.W. Association of galectin-3 expression with melanoma progression and prognosis. Eur. J. Cancer 2012, 48:865-874.
Prieto V.G., Mourad-Zeidan A.A., Melnikova V., Johnson M.M., Lopez A., Diwan A.H., Lazar A.J., Shen S.S., Zhang P.S., Reed J.A., Gershenwald J.E., Raz A., Bar-Eli M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin. Cancer Res. 2006, 12:6709-6715.
Konstantinov K.N., Robbins B.A., Liu F.T. Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Am. J. Pathol. 1996, 148:25-30.
Yamamoto-Sugitani M., Kuroda J., Ashihara E., Nagoshi H., Kobayashi T., Matsumoto Y., Sasaki N., Shimura Y., Kiyota M., Nakayama R., Akaji K., Taki T., Uoshima N., Kobayashi Y., Horiike S., Maekawa T., Taniwaki M. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17468-17473.
Asgarian-Omran H., Forghani P., Hojjat-Farsangi M., Roohi A., Sharifian R.A., Razavi S.M., Jeddi-Tehrani M., Rabbani H., Shokri F. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Invest. 2010, 28:717-725.
Andréasson U., Dictor M., Jerkeman M., Berglund M., Sundström C., Linderoth J., Rosenquist R., Borrebaeck C.A., Ek S. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am. J. Hematol. 2009, 84:803-808.
Clark M.C., Pang M., Hsu D.K., Liu F.T., de Vos S., Gascoyne R.D., Said J., Baum L.G. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012, 120:4635-4644.
Wollina U., Graefe T., Feldrappe S., André S., Wasano K., Kaltner H., Zick Y., Gabius H.J. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J. Cancer Res. Clin. Oncol. 2002, 128:103-110.
Neder L., Marie S.K., Carlotti C.G., Gabbai A.A., Rosemberg S., Malheiros S.M., Siqueira R.P., Oba-Shinjo S.M., Uno M., Aguiar P.H., Miura F., Chammas R., Colli B.O., Silva W.A., Zago M.A. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol. 2004, 14:399-405.
Park S.H., Min H.S., Kim B., Myung J., Paek S.H. Galectin-3: a useful biomarker for differential diagnosis of brain tumors. Neuropathology 2008, 28:497-506.
Lotz M.M., Andrews C.W., Korzelius C.A., Lee E.C., Steele G.D., Clarke A., Mercurio A.M. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3466-3470.
Honjo Y., Inohara H., Akahani S., Yoshii T., Takenaka Y., Yoshida J., Hattori K., Tomiyama Y., Raz A., Kubo T. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin. Cancer Res. 2000, 6:4635-4640.
Mathieu A., Saal I., Vuckovic A., Ransy V., Vereerstraten P., Kaltner H., Gabius H.J., Kiss R., Decaestecker C., Salmon I., Remmelink M. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod. Pathol. 2005, 18:1264-1271.
Liu T.Y., Chen C.Y., Tien H.F., Lin C.W. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009, 54:214-220.
Kim S.W., Park K.C., Jeon S.M., Ohn T.B., Kim T.I., Kim W.H., Cheon J.H. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. Cell Oncol. (Dordr) 2013, 36:169-178.
Rechreche H., Mallo G.V., Montalto G., Dagorn J.C., Iovanna J.L. Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer. Eur. J. Biochem. 1997, 248:225-230.
Satelli A., Rao P.S., Thirumala S., Rao U.S. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int. J. Cancer 2011, 129:799-809.
Laderach D.J., Gentilini L.D., Giribaldi L., Delgado V.C., Nugnes L., Croci D.O., Al Nakouzi N., Sacca P., Casas G., Mazza O., Shipp M.A., Vazquez E., Chauchereau A., Kutok J.L., Rodig S.J., Elola M.T., Compagno D., Rabinovich G.A. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013, 73:86-96.
Bauer A., Kleeff J., Bier M., Wirtz M., Kayed H., Esposito I., Korc M., Hafner M., Hoheisel J.D., Friess H. Identification of malignancy factors by analyzing cystic tumors of the pancreas. Pancreatology 2009, 9:34-44.
Kondoh N., Wakatsuki T., Ryo A., Hada A., Aihara T., Horiuchi S., Goseki N., Matsubara O., Takenaka K., Shichita M., Tanaka K., Shuda M., Yamamoto M. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999, 59:4990-4996.
Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M., Scurry J.P., Scolyer R.A., Smith A.N., Bali A., Vanden Bergh P., Baron-Hay S., Scott C., Fink D., Hacker N.F., Sutherland R.L., O'Brien P.M. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br. J. Cancer 2006, 94:904-913.
Biron-Pain K., Grosset A.A., Poirier F., Gaboury L., St-Pierre Y. Expression and functions of galectin-7 in human and murine melanomas. PLoS One 2013, 8:e63307.
Zhu H., Wu T.C., Chen W.Q., Zhou L.J., Wu Y., Zeng L., Pei H.P. Roles of galectin-7 and S100A9 in cervical squamous carcinoma: Clinicopathological and in vitro evidence. Int. J. Cancer 2013, 132:1051-1059.
Kim S.J., Hwang J.A., Ro J.Y., Lee Y.S., Chun K.H. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013, 4:1461-1471.
Zhu X., Ding M., Yu M.L., Feng M.X., Tan L.J., Zhao F.K. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer 2010, 10:290.
Demers M., Rose A.A., Grosset A.A., Biron-Pain K., Gaboury L., Siegel P.M., St-Pierre Y. Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am. J. Pathol. 2010, 176:3023-3031.
Rorive S., Eddafali B., Fernandez S., Decaestecker C., André S., Kaltner H., Kuwabara I., Liu F.T., Gabius H.J., Kiss R., Salmon I. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod. Pathol. 2002, 15:1294-1301.
Cada Z., Chovanec M., Smetana K., Betka J., Lacina L., Plzák J., Kodet R., Stork J., Lensch M., Kaltner H., André S., Gabius H.J. Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?. Histol. Histopathol. 2009, 24:41-48.
Demers M., Biron-Pain K., Hébert J., Lamarre A., Magnaldo T., St-Pierre Y. Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Res. 2007, 67:2824-2829.
Matsui Y., Ueda S., Watanabe J., Kuwabara I., Ogawa O., Nishiyama H. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res. 2007, 67:1212-1220.
Danguy A., Rorive S., Decaestecker C., Bronckart Y., Kaltner H., Hadari Y.R., Goren R., Zich Y., Petein M., Salmon I., Gabius H.J., Kiss R. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol. Histopathol. 2001, 16:861-868.
Cludts S., Decaestecker C., Mahillon V., Chevalier D., Kaltner H., André S., Remmelink M., Leroy X., Gabius H.J., Saussez S. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. Anticancer Res. 2009, 29:4933-4940.
Dong G.W., Kim J., Park J.H., Choi J.Y., Cho S.I., Lim S.C. Galectin-8 expression in laryngeal squamous cell carcinoma. Clin. Exp. Otorhinolaryngol. 2009, 2:13-19.
Nagy N., Bronckart Y., Camby I., Legendre H., Lahm H., Kaltner H., Hadari Y., Van Ham P., Yeaton P., Pector J.C., Zick Y., Salmon I., Danguy A., Kiss R., Gabius H.J. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002, 50:392-401.
Caulet-Maugendre S., Birolleau S., Corbineau H., Bassen R., Desrues B., Bidon N., Delaval P., Ramée M.P., Brichory F., Dazord L. Immunohistochemical expression of the intracellular component of galectin-8 in squamous cell metaplasia of the bronchial epithelium in neoplastic and benign processes. Pathol. Res. Pract. 2001, 197:797-801.
Nguyen M.C., Tu G.H., Koprivnikar K.E., Gonzalez-Edick M., Jooss K.U., Harding T.C. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol. Immunother. 2010, 59:1313-1323.
Elola M.T., Ferragut F., Cárdenas Delgado V.M., Nugnes L.G., Gentilini L., Laderach D., Troncoso M.F., Compagno D., Wolfenstein-Todel C., Rabinovich G.A. Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol. Histopathol. 2014, 29:1093-1105.
Yang J., Zhu L., Cai Y., Suo J., Jin J. Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. Int. J. Oncol. 2014, 45:1313-1320.
Jiang J., Jin M.S., Kong F., Cao D., Ma H.X., Jia Z., Wang Y.P., Suo J., Cao X. Decreased galectin-9 and increased tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 2013, 8:e81799.
Kageshita T., Kashio Y., Yamauchi A., Seki M., Abedin M.J., Nishi N., Shoji H., Nakamura T., Ono T., Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 2002, 99:809-816.
Zhang Z.Y., Dong J.H., Chen Y.W., Wang X.Q., Li C.H., Wang J., Wang G.Q., Li H.L., Wang X.D. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2012, 13:2503-2509.
Chan S.W., Kallarakkal T.G., Abraham M.T. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. Asian Pac. J. Cancer Prev. 2014, 15:2145-2152.
Terris B., Blaveri E., Crnogorac-Jurcevic T., Jones M., Missiaglia E., Ruszniewski P., Sauvanet A., Lemoine N.R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 2002, 160:1745-1754.
Türeci O., Schmitt H., Fadle N., Pfreundschuh M., Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J. Biol. Chem. 1997, 272:6416-6422.
Heusschen R., Griffioen A.W., Thijssen V.L. Galectin-9 in tumor biology: a jack of multiple trades. Biochim. Biophys. Acta 2013, 1836:177-185.
Ågesen T.H., Berg M., Clancy T., Thiis-Evensen E., Cekaite L., Lind G.E., Nesland J.M., Bakka A., Mala T., Hauss H.J., Fetveit T., Vatn M.H., Hovig E., Nesbakken A., Lothe R.A., Skotheim R.I. CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes Immun. 2011, 12:653-662.
Miwa H.E., Koba W.R., Fine E.J., Giricz O., Kenny P.A., Stanley P. Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. Glycobiology 2013, 23:1477-1490.
Endo K., Kohnoe S., Tsujita E., Watanabe A., Nakashima H., Baba H., Maehara Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005, 25:3117-3121.
Schoeppner H.L., Raz A., Ho S.B., Bresalier R.S. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75:2818-2826.
Camby I., Belot N., Rorive S., Lefranc F., Maurage C.A., Lahm H., Kaltner H., Hadari Y., Ruchoux M.M., Brotchi J., Zick Y., Salmon I., Gabius H.J., Kiss R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol. 2001, 11:12-26.
Kim S.J., Kim D.C., Kim M.C., Jung G.J., Kim K.H., Jang J.S., Kwon H.C., Kim Y.M., Jeong J.S. Fascin expression is related to poor survival in gastric cancer. Pathol. Int. 2012, 62:777-784.
Okada K., Shimura T., Suehiro T., Mochiki E., Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006, 26:1369-1376.
Bresalier R.S., Yan P.S., Byrd J.C., Lotan R., Raz A. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997, 80:776-787.
Strik H.M., Deininger M.H., Frank B., Schluesener H.J., Meyermann R. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J. Neurooncol. 2001, 53:13-20.
Legendre H., Decaestecker C., Nagy N., Hendlisz A., Schüring M.P., Salmon I., Gabius H.J., Pector J.C., Kiss R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod. Pathol. 2003, 16:491-504.
Lotan R., Matsushita Y., Ohannesian D., Carralero D., Ota D.M., Cleary K.R., Nicolson G.L., Irimura T. Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr Res 1991, 213:47-57.
Nakamura M., Inufusa H., Adachi T., Aga M., Kurimoto M., Nakatani Y., Wakano T., Nakajima A., Hida J.I., Miyake M., Shindo K., Yasutomi M. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int. J. Oncol. 1999, 15:143-148.
Bektas S., Bahadir B., Ucan B.H., Ozdamar S.O. CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol. Oncol. Res. 2010, 16:569-577.
Chen J., Tang D., Wang S., Li Q.G., Zhang J.R., Li P., Lu Q., Niu G., Gao J., Ye N.Y., Wang D.R. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour Biol. 2013, 35:2513-2519.
Chen J., Zhou S.J., Zhang Y., Zhang G.Q., Zha T.Z., Feng Y.Z., Zhang K. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J. Gastroenterol. 2013, 19:2073-2079.
Zhang P., Zhang P., Shi B., Zhou M., Jiang H., Zhang H., Pan X., Gao H., Sun H., Li Z. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 2014, 5:e991.
Croci D.O., Morande P.E., Dergan-Dylon S., Borge M., Toscano M.A., Stupirski J.C., Bezares R.F., Avalos J.S., Narbaitz M., Gamberale R., Rabinovich G.A., Giordano M. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 2013, 27:1413-1416.
Schulkens I.A., Heusschen R., van den Boogaart V., van Suylen R., Dingemans A.D., Griffioen A.W., Thijssen V.L. Galectin expression profiling identifies galectin-1 and galectin-9{increment}5 as prognostic factors in stage I/II non-small cell lung cancer. PLoS One 2014, 9:e107988.
Tsai C.J., Sulman E.P., Eifel P.J., Jhingran A., Allen P.K., Deavers M.T., Klopp A.H. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol. Oncol. 2013, 131:645-649.
Kramer M.W., Kuczyk M.A., Hennenlotter J., Serth J., Schilling D., Stenzl A., Merseburger A.S. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol. Rep. 2008, 20:1403-1408.
Kramer M.W., Waalkes S., Serth J., Hennenlotter J., Tezval H., Stenzl A., Kuczyk M.A., Merseburger A.S. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder. Urol. Int. 2011, 87:143-150.
Yamaki S., Fujii T., Yajima R., Hirakata T., Yamaguchi S., Fujisawa T., Tsutsumi S., Asao T., Yanagita Y., Iijima M., Kuwano H. Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg. Today 2012, 43:901-905.
Irie A., Yamauchi A., Kontani K., Kihara M., Liu D., Shirato Y., Seki M., Nishi N., Nakamura T., Yokomise H., Hirashima M. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 2005, 11:2962-2968.
White N.M., Masui O., Newsted D., Scorilas A., Romaschin A.D., Bjarnason G.A., Siu K.W., Yousef G.M. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br. J. Cancer 2014, 110:1250-1259.
Cheng C.L., Hou H.A., Lee M.C., Liu C.Y., Jhuang J.Y., Lai Y.J., Lin C.W., Chen H.Y., Liu F.T., Chou W.C., Chen C.Y., Tang J.L., Yao M., Huang S.Y., Ko B.S., Wu S.J., Tsay W., Tien H.F. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 2013, 121:3172-3180.
Kim M.K., Sung C.O., Do I.G., Jeon H.K., Song T.J., Park H.S., Lee Y.Y., Kim B.G., Lee J.W., Bae D.S. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int. J. Clin. Oncol. 2011, 16:352-358.
Min K.W., Park M.H., Hong S.R., Lee H., Kwon S.Y., Hong S.H., Joo H.J., Park I.A., An H.J., Suh K.S., Oh H.K., Yoo C.W., Kim M.J., Chang H.K., Jun S.Y., Yoon H.K., Chang E.D., Kim D.W., Kim I. Gynecologic Pathology Study Group of the Korean Society of Pathologists, Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int. J. Gynecol. Pathol. 2013, 32:3-14.
Le Q.T., Shi G., Cao H., Nelson D.W., Wang Y., Chen E.Y., Zhao S., Kong C., Richardson D., O'Byrne K.J., Giaccia A.J., Koong A.C. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol. 2005, 23:8932-8941.
Chang S.L., Li C.F., Lin C., Lin Y.S. Galectin-1 overexpression in nasopharyngeal carcinoma: effect on survival. Acta Otolaryngol. 2014, 134:536-542.
Acikalin M.F., Etiz D., Gurbuz M.K., Ozudogru E., Canaz F., Colak E. Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma. Med. Oncol. 2012, 29:742-749.
Piantelli M., Iacobelli S., Almadori G., Iezzi M., Tinari N., Natoli C., Cadoni G., Lauriola L., Ranelletti F.O. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J. Clin. Oncol. 2002, 20:3850-3856.
Buttery R., Monaghan H., Salter D.M., Sethi T. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Histopathology 2004, 44:339-344.
Carlini M.J., Roitman P., Nuñez M., Pallotta M.G., Boggio G., Smith D., Salatino M., Joffé E.D., Rabinovich G.A., Puricelli L.I. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients. Lung Cancer 2014, 84:73-78.
Huang E.Y., Chanchien C.C., Lin H., Wang C.C., Wang C.J., Huang C.C. Galectin-1 is an independent prognostic factor for local recurrence and survival after definitive radiation therapy for patients with squamous cell carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87:975-982.
Makki F.M., Taylor S.M., Shahnavaz A., Leslie A., Gallant J., Douglas S., Teh E., Trites J., Bullock M., Inglis K., Pinto D.M., Hart R.D. Serum biomarkers of papillary thyroid cancer. J. Otolaryngol. Head Neck Surg. 2013, 42:16.
Saussez S., Glinoer D., Chantrain G., Pattou F., Carnaille B., André S., Gabius H.J., Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18:705-712.
Cedeno-Laurent F., Watanabe R., Teague J.E., Kupper T.S., Clark R.A., Dimitroff C.J. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012, 119:3534-3538.
Vereecken P., Zouaoui Boudjeltia K., Debray C., Awada A., Legssyer I., Sales F., Petein M., Vanhaeverbeek M., Ghanem G., Heenen M. High serum galectin-3 in advanced melanoma: preliminary results. Clin. Exp. Dermatol. 2006, 31:105-109.
Sakaki M., Oka N., Nakanishi R., Yamaguchi K., Fukumori T., Kanayama H.O. Serum level of galectin-3 in human bladder cancer. J. Med. Invest. 2008, 55:127-132.
Barrow H., Guo X., Wandall H.H., Pedersen J.W., Fu B., Zhao Q., Chen C., Rhodes J.M., Yu L.G. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin. Cancer Res. 2011, 17:7035-7046.
Chen C., Duckworth C.A., Zhao Q., Pritchard D.M., Rhodes J.M., Yu L.G. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin. Cancer Res. 2013, 19:1693-1704.
Iacovazzi P.A., Notarnicola M., Caruso M.G., Guerra V., Frisullo S., Altomare D.F. Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol. Immunotoxicol. 2010, 32:160-164.
Watanabe M., Takemasa I., Kaneko N., Yokoyama Y., Matsuo E., Iwasa S., Mori M., Matsuura N., Monden M., Nishimura O. Clinical significance of circulating galectins as colorectal cancer markers. Oncol. Rep. 2011, 25:1217-1226.
Bresalier R.S., Byrd J.C., Tessler D., Lebel J., Koomen J., Hawke D., Half E., Liu K.F., Mazurek N. Great Lakes-New England Clinical and Epidemiology Center of the Early Detection Research Network, A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology 2004, 127:741-748.
Carlsson M.C., Cederfur C., Schaar V., Balog C.I., Lepur A., Touret F., Salomonsson E., Deelder A.M., Fernö M., Olsson H., Wuhrer M., Leffler H. Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One 2011, 6:e26560.
Greco C., Vona R., Cosimelli M., Matarrese P., Straface E., Scordati P., Giannarelli D., Casale V., Assisi D., Mottolese M., Moles A., Malorni W. Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 2004, 14:783-792.
Marchetti A., Tinari N., Buttitta F., Chella A., Angeletti C.A., Sacco R., Mucilli F., Ullrich A., Iacobelli S. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 2002, 62:2535-2539.
Ozaki Y., Kontani K., Teramoto K., Fujita T., Tezuka N., Sawai S., Maeda T., Watanabe H., Fujino S., Asai T., Ohkubo I. Involvement of 90K/Mac-2 binding protein in cancer metastases by increased cellular adhesiveness in lung cancer. Oncol. Rep. 2004, 12:1071-1077.
Ozaki Y., Kontani K., Hanaoka J., Chano T., Teramoto K., Tezuka N., Sawai S., Fujino S., Yoshiki T., Okabe H., Ohkubo I. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002, 95:1954-1962.
Wu C.C., Chien K.Y., Tsang N.M., Chang K.P., Hao S.P., Tsao C.H., Chang Y.S., Yu J.S. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5:3173-3182.
Išić T., Savin S., Cvejić D., Marečko I., Tatić S., Havelka M., Paunović I. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J. Cancer Res. Clin. Oncol. 2010, 136:1805-1812.
Inohara H., Segawa T., Miyauchi A., Yoshii T., Nakahara S., Raz A., Maeda M., Miyoshi E., Kinoshita N., Yoshida H., Furukawa M., Takenaka Y., Takamura Y., Ito Y., Taniguchi N. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem. Biophys. Res. Commun. 2008, 376:605-610.
Saussez S., Lorfevre F., Lequeux T., Laurent G., Chantrain G., Vertongen F., Toubeau G., Decaestecker C., Kiss R. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2008, 44:86-93.
Xie L., Ni W.K., Chen X.D., Xiao M.B., Chen B.Y., He S., Lu C.H., Li X.Y., Jiang F., Ni R.Z. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J. Cancer Res. Clin. Oncol. 2012, 138:1035-1043.
de Melo-Júnior M.R., Araújo-Filho J.L., Lins C.A., de Pontes-Filho N.T., de Carvalho L.B. Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis. Appl. Biochem. Biotechnol. 2010, 160:2198-2207.
Gong H.C., Honjo Y., Nangia-Makker P., Hogan V., Mazurak N., Bresalier R.S., Raz A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999, 59:6239-6245.
Lipkowitz M.S., Leal-Pinto E., Cohen B.E., Abramson R.G. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj. J. 2004, 19:491-498.
Menon S., Kang C.M., Beningo K.A. Galectin-3 secretion and tyrosine phosphorylation is dependent on the calpain small subunit, Calpain 4. Biochem. Biophys. Res. Commun. 2011, 410:91-96.
Gao X., Liu D., Fan Y., Li X., Xue H., Ma Y., Zhou Y., Tai G. The two endocytic pathways mediated by the carbohydrate recognition domain and regulated by the collagen-like domain of galectin-3 in vascular endothelial cells. PLoS One 2012, 7:e52430.
Ideo H., Hoshi I., Yamashita K., Sakamoto M. Phosphorylation and externalization of galectin-4 is controlled by Src family kinases. Glycobiology 2013, 23:1452-1462.
Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005, 4:477-488.
Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 2012, 1820:1347-1353.
Plzák J., Betka J., Smetana K., Chovanec M., Kaltner H., André S., Kodet R., Gabius H.J. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur. J. Cancer 2004, 40:2324-2330.
Gordower L., Decaestecker C., Kacem Y., Lemmers A., Gusman J., Burchert M., Danguy A., Gabius H., Salmon I., Kiss R., Camby I. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol. 1999, 25:319-330.
Fritz P., Seizer-Schmidt R., Mürdter T.E., Kroemer H.K., Aulitzky W., André S., Gabius H.J., Friedel G., Toomes H., Siegle I. Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance?. Acta Histochem. 1999, 101:239-253.
André S., Kojima S., Yamazaki N., Fink C., Kaltner H., Kayser K., Gabius H.J. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J. Cancer Res. Clin. Oncol. 1999, 125:461-474.
Ouyang J., Plütschow A., von Strandmann E.P., Reiners K.S., Ponader S., Rabinovich G.A., Neuberg D., Engert A., Shipp M.A. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 2013, 121:3431-3433.
Vereecken P., Awada A., Suciu S., Castro G., Morandini R., Litynska A., Lienard D., Ezzedine K., Ghanem G., Heenen M. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009, 19:316-320.
Iurisci I., Tinari N., Natoli C., Angelucci D., Cianchetti E., Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6:1389-1393.
Senapati S., Chaturvedi P., Chaney W.G., Chakraborty S., Gnanapragassam V.S., Sasson A.R., Batra S.K. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 2011, 17:267-274.
Barrow H., Rhodes J.M., Yu L.G. Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol. (Dordr) 2013, 36:9-13.
Gaida M.M., Bach S.T., Günther F., Baseras B., Tschaharganeh D.F., Welsch T., Felix K., Bergmann F., Hänsch G.M., Wente M.N. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Pathol. Oncol. Res. 2012, 18:299-307.
Verschuere T., Van Woensel M., Fieuws S., Lefranc F., Mathieu V., Kiss R., Van Gool S.W., De Vleeschouwer S. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J. Neurooncol. 2013, 115:9-17.
Paz A., Haklai R., Elad-Sfadia G., Ballan E., Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001, 20:7486-7493.
Newlaczyl A.U., Yu L.G. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011, 313:123-128.
Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251.
Banh A., Zhang J., Cao H., Bouley D.M., Kwok S., Kong C., Giaccia A.J., Koong A.C., Le Q.T. Tumor galectin-1 mediates lung cancer growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011, 71:4423-4431.
Martínez-Bosch N., Fernández-Barrena M.G., Moreno M., Ortiz-Zapater E., Munné-Collado J., Iglesias M., André S., Gabius H.J., Hwang R.F., Poirier F., Navas C., Guerra C., Fernández-Zapico M.E., Navarro P. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 2014, 74:3512-3524.
Dings R.P., Van Laar E.S., Loren M., Webber J., Zhang Y., Waters S.J., Macdonald J.R., Mayo K.H. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug. Chem. 2010, 21:20-27.
Thijssen V.L., Barkan B., Shoji H., Aries I.M., Mathieu V., Deltour L., Hackeng T.M., Kiss R., Kloog Y., Poirier F., Griffioen A.W. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010, 70:6216-6224.
Glinskii O.V., Huxley V.H., Glinsky G.V., Pienta K.J., Raz A., Glinsky V.V. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 2005, 7:522-527.
Glinskii O.V., Sud S., Mossine V.V., Mawhinney T.P., Anthony D.C., Glinsky G.V., Pienta K.J., Glinsky V.V. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia 2012, 14:65-73.
Wu M.H., Hong H.C., Hong T.M., Chiang W.F., Jin Y.T., Chen Y.L. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin. Cancer Res. 2011, 17:1306-1316.
Ito K., Ralph S.J. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin. Exp. Metastasis 2012, 29:561-572.
Liu H.Y., Huang Z.L., Yang G.H., Lu W.Q., Yu N.R. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J. Gastroenterol. 2008, 14:7386-7391.
Pienta K.J., Naik H., Akhtar A., Yamazaki K., Replogle T.S., Lehr J., Donat T.L., Tait L., Hogan V., Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J. Natl. Cancer Inst. 1995, 87:348-353.
Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012, 9:e1001216.
Balan V., Nangia-Makker P., Schwartz A.G., Jung Y.S., Tait L., Hogan V., Raz T., Wang Y., Yang Z.Q., Wu G.S., Guo Y., Li H., Abrams J., Couch F.J., Lingle W.L., Lloyd R.V., Ethier S.P., Tainsky M.A., Raz A. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res. 2008, 68:10045-10050.
Logullo A.F., Lopes A.B., Nonogaki S., Soares F.A., Netto M.M., Nishimoto I.N., Brentani M.M. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncol. Rep. 2007, 18:121-126.
Nangia-Makker P., Wang Y., Raz T., Tait L., Balan V., Hogan V., Raz A. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int. J. Cancer 2010, 127:2530-2541.
Wu F., Hu N., Li Y., Bian B., Xu G., Zheng Y. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol. (Dordr) 2012, 35:175-180.
Wang L.P., Chen S.W., Zhuang S.M., Li H., Song M. Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β-catenin-dependent pathway. Pathol. Oncol. Res. 2013, 19:461-474.
Chiang W.F., Liu S.Y., Fang L.Y., Lin C.N., Wu M.H., Chen Y.C., Chen Y.L., Jin Y.T. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol. 2008, 44:325-334.
Teymoortash A., Pientka A., Schrader C., Tiemann M., Werner J.A. Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J. Cancer Res. Clin. Oncol. 2006, 132:51-56.
Baldus S.E., Zirbes T.K., Weingarten M., Fromm S., Glossmann J., Hanisch F.G., Mönig S.P., Schröder W., Flucke U., Thiele J., Hölscher A.H., Dienes H.P. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000, 21:258-266.
Pan S., Chen R., Reimel B.A., Crispin D.A., Mirzaei H., Cooke K., Coleman J.F., Lane Z., Bronner M.P., Goodlett D.R., McIntosh M.W., Traverso W., Aebersold R., Brentnall T.A. Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009, 30:1132-1144.
Chung J.C., Oh M.J., Choi S.H., Bae C.D. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008, 78:245-251.
Song S., Ji B., Ramachandran V., Wang H., Hafley M., Logsdon C., Bresalier R.S. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012, 7:e42699.
Shimamura T., Sakamoto M., Ino Y., Shimada K., Kosuge T., Sato Y., Tanaka K., Sekihara H., Hirohashi S. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. 2002, 8:2570-2575.
Schaffert C., Pour P.M., Chaney W.G. Localization of galectin-3 in normal and diseased pancreatic tissue. Int. J. Pancreatol. 1998, 23:1-9.
Merlin J., Stechly L., de Beaucé S., Monté D., Leteurtre E., van Seuningen I., Huet G., Pigny P. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011, 30:2514-2525.
Hann A., Gruner A., Chen Y., Gress T.M., Buchholz M. Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells. PLoS One 2011, 6:e20859.
Yang L.P., Jiang S., Liu J.Q., Miao X.Y., Yang Z.L. Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma. Hepatogastroenterology 2012, 59:2089-2094.
Kondoh N., Hada A., Ryo A., Shuda M., Arai M., Matsubara O., Kimura F., Wakatsuki T., Yamamoto M. Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. Int. J. Oncol. 2003, 23:1575-1583.
Shimonishi T., Miyazaki K., Kono N., Sabit H., Tuneyama K., Harada K., Hirabayashi J., Kasai K., Nakanuma Y. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum. Pathol. 2001, 32:302-310.
Hsu D.K., Dowling C.A., Jeng K.C., Chen J.T., Yang R.Y., Liu F.T. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer 1999, 81:519-526.
Hittelet A., Legendre H., Nagy N., Bronckart Y., Pector J.C., Salmon I., Yeaton P., Gabius H.J., Kiss R., Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 2003, 103:370-379.
Arfaoui-Toumi A., Kria-Ben Mahmoud L., Ben Hmida M., Khalfallah M.T., Regaya-Mzabi S., Bouraoui S. Implication of the Galectin-3 in colorectal cancer development. Bull. Cancer 2010, 97:E1-E8.
Fernandez-Aguilar S., Noël J.C. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS 2008, 116:33-40.
Castronovo V., Van Den BrÛle F.A., Jackers P., Clausse N., Liu F.T., Gillet C., Sobel M.E. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 1996, 179:43-48.
Mayoral M.A., Mayoral C., Meneses A., Villalvazo L., Guzman A., Espinosa B., Ochoa J.L., Zenteno E., Guevara J. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Invest. 2008, 26:615-623.
van den BrÛle F., Califice S., Garnier F., Fernandez P.L., Berchuck A., Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 2003, 83:377-386.
van den BrÛle F.A., Berchuck A., Bast R.C., Liu F.T., Gillet C., Sobel M.E., Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur. J. Cancer 1994, 30A:1096-1099.
Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int. J. Gynecol. Pathol. 2008, 27:380-389.
Cortesi L., Rossi E., Della Casa L., Barchetti A., Nicoli A., Piana S., Abrate M., La Sala G.B., Federico M., Iannone A. Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis 2011, 32:1992-2003.
Weissenbacher T., Kuhn C., Mayr D., Pavlik R., Friese K., Scholz C., Jeschke U., Ditsch N., Dian D. Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. Anticancer Res. 2011, 31:451-457.
Ege C.B., Akbulut M., Zekioğlu O., Ozdemir N. Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival. Arch. Gynecol. Obstet. 2011, 284:1231-1239.
Brustmann H., Riss D., Naudé S. Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. Pathol. Res. Pract. 2003, 199:151-158.
Kim H.J., Do I.G., Jeon H.K., Cho Y.J., Park Y.A., Choi J.J., Sung C.O., Lee Y.Y., Choi C.H., Kim T.J., Kim B.G., Lee J.W., Bae D.S. Galectin-1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum. Pathol. 2013, 44:62-68.
Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim T.J., Kim J., Lee J.H., Kim B.G., Bae D.S. Decreased galectin-3 expression during the progression of cervical neoplasia. J. Cancer Res. Clin. Oncol. 2006, 132:241-247.
Liang M., Ueno M., Oomizu S., Arikawa T., Shinonaga R., Zhang S., Yamauchi A., Hirashima M. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:899-907.
Ellerhorst J., Troncoso P., Xu X.C., Lee J., Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol. Res. 1999, 27:362-367.
Clausse N., van den BrÛle F., Waltregny D., Garnier F., Castronovo V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 1999, 3:317-325.
van den BrÛle F.A., Waltregny D., Liu F.T., Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int. J. Cancer 2000, 89:361-367.
Ahmed H., Cappello F., Rodolico V., Vasta G.R. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl. Oncol. 2009, 2:146-156.
Pacis R.A., Pilat M.J., Pienta K.J., Wojno K., Raz A., Hogan V., Cooper C.R. Decreased galectin-3 expression in prostate cancer. Prostate 2000, 44:118-123.
Merseburger A.S., Kramer M.W., Hennenlotter J., Simon P., Knapp J., Hartmann J.T., Stenzl A., Serth J., Kuczyk M.A. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 2008, 68:72-77.
Knapp J.S., Lokeshwar S.D., Vogel U., Hennenlotter J., Schwentner C., Kramer M.W., Stenzl A., Merseburger A.S. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J. Urol. 2013, 31:351-358.
Su Z.Z., Lin J., Shen R., Fisher P.E., Goldstein N.I., Fisher P.B. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:7252-7257.
Saussez S., Decaestecker C., Lorfevre F., Chevalier D., Mortuaire G., Kaltner H., André S., Toubeau G., Gabius H.J., Leroy X. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008, 52:483-493.
Miranda F.A., Hassumi M.K., Guimarães M.C., Simões R.T., Silva T.G., Lira R.C., Rocha A.M., Mendes C.T., Donadi E.A., Soares C.P., Soares E.G. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis. J. Histochem. Cytochem. 2009, 57:665-673.
Bassen R., Brichory F., Caulet-Maugendre S., Bidon N., Delaval P., Desrues B., Dazord L. Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues. Anticancer Res. 1999, 19:5429-5433.
Tews D.S. Adhesive and invasive features in gliomas. Pathol. Res. Pract. 2000, 196:701-711.
Riss D., Jin L., Qian X., Bayliss J., Scheithauer B.W., Young W.F., Vidal S., Kovacs K., Raz A., Lloyd R.V. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003, 63:2251-2255.
Merseburger A.S., Kramer M.W., Hennenlotter J., Serth J., Kruck S., Gracia A., Stenzl A., Kuczyk M.A. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J. Urol. 2008, 26:637-642.
Straube T., Elli A.F., Greb C., Hegele A., Elsässer H.P., Delacour D., Jacob R. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J. Exp. Clin. Cancer Res. 2011, 30:89.
Sakaki M., Fukumori T., Fukawa T., Elsamman E., Shiirevnyamba A., Nakatsuji H., Kanayama H.O. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J. Med. Invest. 2010, 57:152-157.
Saffar H., Sanii S., Heshmat R., Haghpanah V., Larijani B., Rajabiani A., Azimi S., Tavangar S.M. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma. Am. J. Clin. Pathol. 2011, 135:454-460.
Juszczynski P., Rodig S.J., Ouyang J., O'Donnell E., Takeyama K., Mlynarski W., Mycko K., Szczepanski T., Gaworczyk A., Krivtsov A., Faber J., Sinha A.U., Rabinovich G.A., Armstrong S.A., Kutok J.L., Shipp M.A. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin. Cancer Res. 2010, 16:2122-2130.
Kim S.J., Lee S.J., Sung H.J., Choi I.K., Choi C.W., Kim B.S., Kim J.S., Yu W., Hwang H.S., Kim I.S. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008, 120:211-216.
Than T.H., Swethadri G.K., Wong J., Ahmad T., Jamil D., Maganlal R.K., Hamdi M.M., Abdullah M.S. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singap. Med. J. 2008, 49:333-338.
Zhu X., Sun T., Lu H., Zhou X., Lu Y., Cai X., Zhu X. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J. Clin. Pathol. 2010, 63:786-789.
Abulkheir I.L., Mohammad D.B. Value of immunohistochemical expression of p27 and galectin-3 in differentiation between follicular adenoma and follicular carcinoma. Appl. Immunohistochem. Mol. Morphol. 2012, 20:131-140.
Vereecken P., Debray C., Petein M., Awada A., Lalmand M.C., Laporte M., Van Den Heule B., Verhest A., Pochet R., Heenen M. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch. Dermatol. Res. 2005, 296:353-358.
Balan V., Wang Y., Nangia-Makker P., Kho D., Bajaj M., Smith D., Heilbrun L., Raz A., Heath E. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 2013, 4:542-549.
Fei F., Abdel-Azim H., Lim M., Arutyunyan A., von Itzstein M., Groffen J., Heisterkamp N. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 2013, 27:2385-2388.
Sheng T.H., Rong L.X., Li Z.Y., Bo J., Lei S. Tissue and serum galectin-1 expression in patients with colorectal carcinoma. Hepatogastroenterology 2012, 59:389-394.
Allen H.J., Sharma A., Ahmed H., Piver M.S., Gamarra M. Galaptin and galaptin-binding glycoconjugates in serum and effusions of carcinoma patients. Tumour Biol. 1993, 14:360-368.
Koopmann J., Thuluvath P.J., Zahurak M.L., Kristiansen T.Z., Pandey A., Schulick R., Argani P., Hidalgo M., Iacobelli S., Goggins M., Maitra A. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004, 101:1609-1615.
